The APOB Knockout A-549 Polyclonal Cells constitute a genetically modified human cell population derived from the A-549 lung adenocarcinoma line, featuring targeted disruption of the APOB gene via CRISPR/Cas9 technology. This polyclonal knockout product provides a loss-of-function model without clonal selection, preserving the genetic heterogeneity typical of cancer cell populations. The disruption eliminates functional APOB protein, enabling systematic investigation of apolipoprotein B-dependent processes in a lung epithelial adenocarcinoma background.
The parental A-549 cell line was originally established from the tumor tissue of a 58-year-old Caucasian male with lung adenocarcinoma. These cells exhibit characteristics of alveolar type II epithelial cells and are extensively utilized for respiratory disease research, drug metabolism studies, and cancer biology. A-549 cells retain expression of relevant lipoprotein receptors and cholesterol regulatory machinery, making them an appropriate host for exploring lipid metabolism in non-hepatic contexts.
APOB encodes apolipoprotein B, the major protein component of low-density lipoproteins (LDL). Acting as a high-affinity ligand for the LDL receptor (LDLR), APOB mediates the clathrin-mediated endocytosis of LDL particles, delivering cholesterol to cells. This uptake is integrated with cellular cholesterol sensing: when intracellular cholesterol is low, SCAP escorts SREBP-2 to the Golgi for proteolytic activation, leading to transcriptional upregulation of LDLR and APOB itself. Conversely, high cholesterol suppresses SREBP-2 processing. Key regulators of APOB expression include the transcription factors SREBP-2 and HNF4A, while insulin and statins modulate its production post-transcriptionally. APOB physically interacts with microsomal triglyceride transfer protein (MTP) during lipoprotein assembly and is functionally linked to PCSK9, which targets LDLR for lysosomal degradation, and apolipoprotein(a), forming atherogenic Lp(a) particles. Downstream of APOB, LDLR availability and intracellular cholesterol levels dictate SREBP-2 activity, creating a tightly controlled feedback loop.
In the context of A-549 lung adenocarcinoma cells, APOB knockout allows researchers to dissect the contribution of exogenous cholesterol uptake to tumor cell proliferation, membrane synthesis, and statin response. Lung cancers often rewire lipid metabolism for growth advantages, and this model provides a clean background to study LDLR signaling independent of its canonical ligand. It also facilitates interrogation of crosstalk between lipoprotein-derived cholesterol and the SREBP-2-driven endogenous synthesis pathway, potentially revealing synthetic lethal interactions or vulnerabilities to lipid-disrupting agents.
Practical applications of these polyclonal knockout cells span functional validation via Western blot and RT-qPCR for APOB mRNA, LDL uptake assays with fluorescently labeled LDL, and quantitative cholesterol measurements. Proliferation assays under statin treatment can assess drug sensitivity, while RNA-seq enables global transcriptomic profiling. The model is relevant for investigating familial hypercholesterolemia, hypobetalipoproteinemia, atherosclerosis, and coronary artery disease in vitro, as well as lipid-driven oncogenic mechanisms. For additional details, please contact Ascent Research.
